January 30, 2025
Headlines

Healthtech

cureosity_team

CUREOSITY Secures €3.8 Million Investment to Propel VR Therapy Innovations

Editor06 mins

In a significant stride towards revolutionizing therapeutic interventions, medtech innovator CUREOSITY has announced securing an additional €3.8 million in funding, catapulting its total investment to over €8.4 million. Specializing in the development of virtual reality (VR) therapy enhanced by gamification, CUREOSITY integrates cutting-edge neuroscientific discoveries, particularly harnessing the power of neuroplasticity, with decades of therapeutic…

Read More

EpilepsyGTx Secures $10M to Advance Breakthrough Gene Therapy for Focal Refractory Epilepsy

Editor05 mins

EpilepsyGTx, a pioneering biotechnology firm specializing in advanced gene therapies for focal refractory epilepsy, has announced a successful $10 million seed funding round. The financing, spearheaded by the UCL Technology Fund and bolstered by Health Technology Holding, marks a significant milestone in the company’s journey towards combating this challenging neurological disorder. Led by CEO Nicolas…

Read More

OCON Therapeutics Secures $10M to Revolutionize Women’s Health with Advanced Drug Delivery Solutions

Editor06 mins

OCON Therapeutics, a pioneer recognized by the World Economic Forum for its advancements in drug delivery, has announced a significant milestone with the completion of a $10 million investment round led by RH Capital. This funding marks a pivotal moment for OCON as it accelerates efforts to redefine the standard of care in women’s health…

Read More

Vico Therapeutics Secures €65.8 Million in Series B Funding to Advance Groundbreaking Neurological Therapies

Editor04 mins

Vico Therapeutics, a pioneering clinical-stage genetic medicines company, has successfully closed its Series B funding round with a total investment of €65.8 million ($70.7 million). This financing round, led by Seroba and Kurma Partners, marks a significant milestone in Vico’s journey towards developing transformative therapies for severe neurological diseases. Vico Therapeutics specializes in antisense oligonucleotide…

Read More

Ethris GmbH: Leading the Charge in mRNA-Based Therapeutics with $5 Million Investment

Editor04 mins

Since its inception, Ethris GmbH has been a trailblazer in mRNA technology, revolutionizing the biotech landscape with its innovative approach to respiratory and cardiovascular diseases. Founded on a vision of harnessing messenger RNA (mRNA) for therapeutic breakthroughs, Ethris has consistently pushed boundaries, drawing attention from investors and global biotech leaders alike. Breakthroughs and Strategic Growth…

Read More

PolTREG Reports Long-Term Success in Type-1 Diabetes Treatment Study

Editor03 mins

PolTREG S.A., a pioneering biotechnology firm specializing in cellular therapies for autoimmune disorders, has announced groundbreaking findings from its long-term clinical study on PTG-007, a polyclonal Treg cell therapy for early-onset type-1 diabetes (T1D). Over a span of 7 to 12 years, pediatric patients treated with PTG-007 demonstrated sustained insulin secretion, contrasting starkly with a…

Read More

Marea Therapeutics Secures $190 Million to Propel Novel Cardiovascular Treatments

Editor04 mins

Marea Therapeutics has marked a significant milestone with the successful closure of a $190 million combined Series A and B financing, positioning the clinical-stage biotechnology firm to accelerate its pioneering efforts in cardiometabolic disease treatments. Led by Third Rock Ventures and supported by a consortium of leading investors including Sofinnova Investments, Forbion, and Perceptive Xontogeny…

Read More